Dr Henderson joins the Cytokinetics board of directors with over 30 years of experience in the life science industry. Since December 2000, Dr Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm.
Dr Henderson has earned his bachelor’s and medical degrees from the University of Edinburgh and is a fellow of the Royal College of Physicians, Edinburgh.
Robert Blum, president and CEO of Cytokinetics, said: “We are pleased to welcome John to our board of directors at this important time in the maturation of our company. Given his diverse experiences in matters relating to global pharmaceutical clinical development and medical affairs, we are pleased that we can benefit from his knowledgeable insights and contributions as our drug candidates may advance from proof-of-concept stage clinical trials toward potential registration and commercialization activities.”